Immunological Characterization and Neutralizing Ability of Monoclonal Antibodies Directed Against Botulinum Neurotoxin Type H

Journal of Infectious Diseases

Volumn 213, Issue 10, 2016, Pages 1606-1614

  Fan, Yongfeng ^a   Barash, Jason R ^b   Lou, Jianlong ^a   Conrad, Fraser ^a   Marks, James D ^a   Arnon, Stephen S ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NATL CENTER FOR INFECTIOUS DISEASES   (United States)

Author keywords

Bioterrorism; Botulinum neurotoxin type H; Botulinum toxin; Botulism; Clostridium botulinum; Monoclonal antibodies; Select agents

Indexed keywords

BOTULINUM NEUROTOXIN TYPE H; BOTULINUM TOXIN; BOTULINUM TOXIN A; BOTULINUM TOXIN F; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 4E17.2A; MONOCLONAL ANTIBODY 4E17.2B; MONOCLONAL ANTIBODY 4E17.2C; MONOCLONAL ANTIBODY 4E17.2D; MONOCLONAL ANTIBODY CR2; MONOCLONAL ANTIBODY RAZ1; UNCLASSIFIED DRUG; ANTITOXIN; NEUTRALIZING ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; BOTULISM; DRUG BINDING; IMMUNITY; IMMUNOGENICITY; MOUSE; NEUTRALIZATION; NONHUMAN; PRIORITY JOURNAL; ANIMAL; CHEMISTRY; CLOSTRIDIUM BOTULINUM; DISEASE MODEL; GOAT; HORSE; HUMAN; IMMUNOLOGY;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; ANTITOXINS; BOTULINUM TOXINS; BOTULISM; CLOSTRIDIUM BOTULINUM; DISEASE MODELS, ANIMAL; GOATS; HORSES; HUMANS; MICE;

EID: 84969939696     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiv770     Document Type: Article

References (43)

1. Gill DM. Bacterial toxins: a table of lethal amounts. Microbiol Rev 1982; 46:86-94.
2. Lacy DB, Tepp W, Cohen AC, DasGupta BR, Stevens RC. Crystal structure of botulinum neurotoxin type A and implications for toxicity. Nat Struct Biol 1998; 5:898-902.
3. Dolly JO, Black J,Williams RS, Melling J. Acceptors for botulinum neurotoxin reside on motor nerve terminals and mediate its internalization. Nature 1984; 307:457-60.
4. Dong M, Yeh F, Tepp WH, et al. SV2 is the protein receptor for botulinum neurotoxin A. Science 2006; 312:592-6.
5. Montecucco C, Rossetto O, Schiavo G. Presynaptic receptor arrays for clostridial neurotoxins. Trends Microbiol 2004; 12:442-6.
6. Mahrhold S, Rummel A, Bigalke H, Davletov B, Binz T. The synaptic vesicle protein 2C mediates the uptake of botulinum neurotoxin A into phrenic nerves. FEBS Lett 2006; 580:2011-4.
7. Blaustein RO, Germann WJ, Finkelstein A, DasGupta BR. The N-terminal half of the heavy chain of botulinum type A neurotoxin forms channels in planar phospholipid bilayers. FEBS Lett 1987; 226:115-20.
8. Fischer A, Montal M. Single molecule detection of intermediates during botulinum neurotoxin translocation across membranes. Proc Natl Acad Sci U S A 2007; 104:10447-52.
9. Simpson LL. Kinetic studies on the interaction between botulinum toxin type A and the cholinergic neuromuscular junction. J Pharmacol Exp Ther 1980; 212:16-21.
10. Schiavo G, Benfenati F, Poulain B, et al. Tetanus and botulinum-B neurotoxins block neurotransmitter release by proteolytic cleavage of synaptobrevin. Nature 1992; 359:832-5.
11. Burke GS. Notes on Bacillus botulinus. J Bacteriol 1919; 4:555-70.
12. Burke GS. The occurrence of Bacillus botulinus in nature. J Bacteriol 1919; 4:541-53.
13. Giménez DF, Ciccarelli AS. Another type of Clostridium botulinum. Zentralbl Bakteriol Orig 1970; 215:221-4.
14. Moller V, Scheibel I. Preliminary report on the isolation of an apparently new type of CI. botulinum. Acta Pathol Microbiol Scand 1960; 48:80.
15. Barash JR, Arnon SS. A novel strain of Clostridium botulinum that produces type B and type H botulinum toxins. J Infect Dis 2014; 209:183-91.
16. Dover N, Barash JR, Hill KK, Xie G, Arnon SS. Molecular characterization of a novel botulinum neurotoxin type H gene. J Infect Dis 2014; 209:192-202.
17. Lacy DB, Stevens RC. Sequence homology and structural analysis of the clostridial neurotoxins. J Mol Biol 1999; 291:1091-104.
18. Maslanka SE, Lúquez C, Dykes JK, et al. A novel botulinum neurotoxin, previously reported as serotype H, has a hybrid-like structure with regions of similarity to the structures of serotypes A and F and is neutralized with serotype A antitoxin. J Infect Dis 2016; 213:379-85.
19. Hill KK, Smith TJ. Genetic diversity within Clostridium botulinum serotypes, botulinum neurotoxin gene clusters and toxin subtypes. Curr Top Microbiol Immunol 2013; 364:1-20.
20. Chen S. Clinical uses of botulinum neurotoxins: current indications, limitations and future developments. Toxins (Basel) 2012; 4:913-39.
21. Arnon SS, Schechter R, Inglesby T, et al. Botulinum toxin as a biological weapon: medical and public health management. JAMA 2001; 285:1059-70.
22. HHS select agents and toxins. 42 Code of Federal Regulations, Part 73 ed. 2012.
23. Adalja AA, Toner E, Inglesby TV. Clinical management of potential bioterrorismrelated conditions. N Engl J Med 2015; 372:954-62.
24. Full prescribing information: botulism antitoxin heptavalent (A, B, C, D, E, F, G)-(equine). http://www.fda.gov/downloads/BiologicsBloodVaccines/ BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/Fractionated PlasmaProducts/UCM345147.pdf. Accessed 22 January 2016.
25. Fagan RP, Neil KP, Sasich R, et al. Initial recovery and rebound of type F intestinal colonization botulism after administration of investigational heptavalent botulinum antitoxin. Clin Infect Dis 2011; 53:e125-8.
26. Nowakowski A, Wang C, Powers DB, et al. Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibody. Proc Natl Acad Sci U S A 2002; 99:11346-50.
27. Nayak SU, Griffiss JM, McKenzie R, et al. Safety and pharmacokinetics of XOMA 3AB, a novel mixture of three monoclonal antibodies against botulinum toxin A. Antimicrob Agents Chemother 2014; 58:5047-53.
28. Meng Q, Garcia-Rodriguez C, Manzanarez G, et al. Engineered domain based assays to identify individual antibodies in oligoclonal combinations targeting the same protein. Anal Biochem 2012; 430:141-50.
29. Razai A, Garcia-Rodriguez C, Lou J, et al. Molecular evolution of antibody affinity for sensitive detection of botulinum neurotoxin type A. J Mol Biol 2005; 351:158-69.
30. Cheng LW, Stanker LH, Henderson TD, Lou J, Marks JD. Antibody protection against botulinum neurotoxin intoxication in mice. Infect Immun 2009; 77:4305-13.
31. Blake RC, Pavlov AR, Blake DA. Automated kinetic exclusion assays to quantify protein binding interactions in homogeneous solution. Anal Biochem 1999; 272:123-34.
32. Garcia-Rodriguez C, Geren IN, Lou J, et al. Neutralizing human monoclonal antibodies binding multiple serotypes of botulinum neurotoxin. Protein Eng Des Sel 2011; 24:321-31.
33. Boder ET, Wittrup KD. Yeast surface display for directed evolution of protein expression, affinity, and stability. Methods Enzymol 2000; 328:430-4.
34. Gonzalez-Escalona N, Thirunavukkarasu N, Singh A, et al. Draft genome sequence of bivalent Clostridium botulinum strain IBCA10-7060, encoding botulinum neurotoxin B and a new FA mosaic type. Genome Announc 2014; 2:e01275-14.
35. Raphael BH, Bradshaw M, Kalb SR, et al. Clostridium botulinum strains producing BoNT/F4 or BoNT/F5. Appl Environ Microbiol 2014; 80:3250-7.
36. Amersdorfer P,Wong C, Smith T, et al. Genetic and immunological comparison of anti-botulinum type A antibodies from immune and non-immune human phage libraries. Vaccine 2002; 20:1640-8.
37. Garcia-Rodriguez C, Levy R, Arndt JW, et al. Molecular evolution of antibody cross-reactivity for two subtypes of type A botulinum neurotoxin. Nat Biotechnol 2007; 25:107-16.
38. Levy R, Forsyth CM, LaPorte SL, Geren IN, Smith LA, Marks JD. Fine and domain-level epitope mapping of botulinum neurotoxin type A neutralizing antibodies by yeast surface display. J Mol Biol 2007; 365:196-210.
39. Kalb SR, Garcia-Rodriguez C, Lou J, et al. Extraction of BoNT/A, /B, /E, and /F with a single, high affinity monoclonal antibody for detection of botulinum neurotoxin by Endopep-MS. PLoS One 2010; 5:e12237.
40. Kalb SR, Baudys J, Raphael BH, et al. Functional characterization of botulinum neurotoxin serotype H as a hybrid of known serotypes F and A (BoNT F/A). Anal Chem 2015; 87:3911-7.
41. Hatheway CL, Snyder JD, Seals JE, Edell TA, Lewis GE Jr. Antitoxin levels in botulism patients treated with trivalent equine botulism antitoxin to toxin types A, B, and E. J Infect Dis 1984; 150:407-12.
42. Sheth AN, Wiersma P, Atrubin D, et al. International outbreak of severe botulism with prolonged toxemia caused by commercial carrot juice. Clin Infect Dis 2008; 47:1245-51.
43. Fagan RP, McLaughlin JB, Middaugh JP. Persistence of botulinum toxin in patients' serum: Alaska, 1959-2007. J Infect Dis 2009; 199:1029-31.